Definitive Healthcare met Q4 earnings but lowered 2026 guidance, causing its stock to drop despite strong cash and demand.

Definitive Healthcare reported Q4 2025 adjusted EPS of $0.06, meeting expectations, and revenue of $61.53 million, slightly above estimates. For Q1 2026, it projected EPS of $0.03, below the $0.05 consensus, and revenue of $54M–$56M, short of $57.2M expected. Full-year 2026 EPS guidance was lowered to $0.14–$0.17, below the $0.21 consensus. Despite strong liquidity—$163.6 million in cash, up 55% year-over-year—and stable demand, the stock dropped to $1.40 on heavy volume. Institutional ownership remains high at 98.67%, but analysts maintain a mixed outlook, with a consensus “hold” rating and a target price of $3.94. The company provides healthcare data analytics via a cloud platform.